Engineering T Cells to Functionally Cure HIV-1 Infection
| Autor: | Rachel S. Leibman, James L. Riley |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
T-Lymphocytes
Cell- and Tissue-Based Therapy Human immunodeficiency virus (HIV) Priming (immunology) HIV Infections Review Virus Replication medicine.disease_cause Immune system Drug Discovery Genetics medicine Humans Cell Engineering Molecular Biology Gene Pharmacology Health consequences Treatment regimen business.industry Antiretroviral therapy Viral replication Immunology HIV-1 Molecular Medicine business |
| Zdroj: | Molecular Therapy. 23:1149-1159 |
| ISSN: | 1525-0016 |
| DOI: | 10.1038/mt.2015.70 |
| Popis: | Despite the ability of antiretroviral therapy to minimize human immunodeficiency virus type 1 (HIV-1) replication and increase the duration and quality of patients' lives, the health consequences and financial burden associated with the lifelong treatment regimen render a permanent cure highly attractive. Although T cells play an important role in controlling virus replication, they are themselves targets of HIV-mediated destruction. Direct genetic manipulation of T cells for adoptive cellular therapies could facilitate a functional cure by generating HIV-1–resistant cells, redirecting HIV-1–specific immune responses, or a combination of the two strategies. In contrast to a vaccine approach, which relies on the production and priming of HIV-1–specific lymphocytes within a patient's own body, adoptive T-cell therapy provides an opportunity to customize the therapeutic T cells prior to administration. However, at present, it is unclear how to best engineer T cells so that sustained control over HIV-1 replication can be achieved in the absence of antiretrovirals. This review focuses on T-cell gene-engineering and gene-editing strategies that have been performed in efforts to inhibit HIV-1 replication and highlights the requirements for a successful gene therapy–mediated functional cure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|